Journal: BioMed Research International

Article Title: Establishment and Verification of a Gene Signature for Diagnosing Type 2 Diabetics by WGCNA, LASSO Analysis, and In Vitro Experiments

doi: 10.1155/2022/4446342

Figure Lengend Snippet: Correlation between the genes in the LASSO model and immune cell infiltrations in type 2 diabetic islets. (a) Heatmap for the associations between hub genes and immune cell infiltrations. Red: positive correlation and blue: negative correlation. (b) Associations between BST2 expression and immune cell infiltrations. (c) Associations between BTBD1 expression and immune cell infiltrations. (d) Associations between IFIT1 expression and immune cell infiltrations. (e) Associations between IFIT3 expression and immune cell infiltrations. (f) Associations between RTP4 expression and immune cell infiltrations. The bigger the circle, the stronger the correlation.

Article Snippet: Two hours later, the membrane was incubated by primary antibodies against BST2 (1/1000; #19277; Cell Signaling Technology, USA), BTBD1 (1/1000; #ab138507; Abcam, USA), TGF- β (1/1000; #84912; Cell Signaling Technology, USA), P53 (1/1000; #2527; Cell Signaling Technology, USA), and GAPDH (1/1000; #5174; Cell Signaling Technology, USA) at 4°C overnight, followed by being incubated by secondary antibodies (1/5 000; ab709; Abcam, USA).

Techniques: Expressing

Journal: BioMed Research International

Article Title: Establishment and Verification of a Gene Signature for Diagnosing Type 2 Diabetics by WGCNA, LASSO Analysis, and In Vitro Experiments

doi: 10.1155/2022/4446342

Figure Lengend Snippet: Expression and involved signaling pathways for the genes in the LASSO model in type 2 diabetic islets. (a) Box plot of the expression of the genes in the LASSO model BST2, BTBD1, IFIT1, IFIT3, and RTP4 between type 2 diabetic islets and normal islets. Ns: Not significant; ∗∗ p < 0.01. (b)–(f) GSEA for identifying the signaling pathways that were positively associated with (b) BST2, (c) BTBD1, (d) IFIT1, (e) IFIT3, and (f) RTP4.

Article Snippet: Two hours later, the membrane was incubated by primary antibodies against BST2 (1/1000; #19277; Cell Signaling Technology, USA), BTBD1 (1/1000; #ab138507; Abcam, USA), TGF- β (1/1000; #84912; Cell Signaling Technology, USA), P53 (1/1000; #2527; Cell Signaling Technology, USA), and GAPDH (1/1000; #5174; Cell Signaling Technology, USA) at 4°C overnight, followed by being incubated by secondary antibodies (1/5 000; ab709; Abcam, USA).

Techniques: Expressing

Journal: BioMed Research International

Article Title: Establishment and Verification of a Gene Signature for Diagnosing Type 2 Diabetics by WGCNA, LASSO Analysis, and In Vitro Experiments

doi: 10.1155/2022/4446342

Figure Lengend Snippet: Validation of the expression of the genes in the LASSO model in glucotoxicity models and normal islet β cells. (a) and (b) RT-qPCR for validating the mRNA expression of (a) BST2 and (b) BTBD1 in glucotoxicity models and normal islet β cells. (c) Representative images of western blot of BST2 and BTBD1 in glucotoxicity models and normal islet β cells. (d) and (e) Quantification results of BST2 and BTBD1 expression in two groups according to western blot. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001.

Article Snippet: Two hours later, the membrane was incubated by primary antibodies against BST2 (1/1000; #19277; Cell Signaling Technology, USA), BTBD1 (1/1000; #ab138507; Abcam, USA), TGF- β (1/1000; #84912; Cell Signaling Technology, USA), P53 (1/1000; #2527; Cell Signaling Technology, USA), and GAPDH (1/1000; #5174; Cell Signaling Technology, USA) at 4°C overnight, followed by being incubated by secondary antibodies (1/5 000; ab709; Abcam, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot

Journal: BioMed Research International

Article Title: Establishment and Verification of a Gene Signature for Diagnosing Type 2 Diabetics by WGCNA, LASSO Analysis, and In Vitro Experiments

doi: 10.1155/2022/4446342

Figure Lengend Snippet: Silencing BST2 ameliorates apoptosis of glucotoxicity islet β cell models and influences the activation of TGF- β and P53 pathways. (a) RT-qPCR of the expression of BST2 mRNA in islet β cells with si-NC or si-BST2 transfection. (b) and (c) Flow cytometry of apoptotic levels of glucotoxicity models and normal islet β cells. (d) and (e) Flow cytometry of apoptotic levels of glucotoxicity models under si-NC or si-BST2 transfection. (f)–(h) Western blot of the expression of TGF- β and P53 proteins in glucotoxicity models and normal islet β cells. (i)–(k) Western blot of the expression of TGF- β and P53 proteins in glucotoxicity models under si-NC or si-BST2 transfection. ∗∗ p < 0.01; ∗∗∗ p < 0.001.

Article Snippet: Two hours later, the membrane was incubated by primary antibodies against BST2 (1/1000; #19277; Cell Signaling Technology, USA), BTBD1 (1/1000; #ab138507; Abcam, USA), TGF- β (1/1000; #84912; Cell Signaling Technology, USA), P53 (1/1000; #2527; Cell Signaling Technology, USA), and GAPDH (1/1000; #5174; Cell Signaling Technology, USA) at 4°C overnight, followed by being incubated by secondary antibodies (1/5 000; ab709; Abcam, USA).

Techniques: Activation Assay, Quantitative RT-PCR, Expressing, Transfection, Flow Cytometry, Western Blot